Skip to main content

31-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Three-year data from CheckMate 227

Suresh Ramalingam outlines the key findings from the 3-year update of the CheckMate 227 trial of first-line nivolumab and ipilimumab in advanced non-small-cell lung cancer (6:50).

Read transcript

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits